Former President and Chief Executive Officer · Oruka Therapeutics, Inc. (ORKA)

Michael Bristow

A named executive officer of Oruka Therapeutics in every fiscal year CompBrief holds from FY2018 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$510,416

Salary $96,865Stock awards $0

FY2023: $358,800

4th of 6 named executive officers at Oruka Therapeutics by FY2024 total.

6 named officers on file for Oruka Therapeutics, FY2024

Michael Bristow’s pay file — $29

  • 7 fiscal years of pay, line by line
  • ORKA’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Oruka Therapeutics’s whole pay program stands against its peers

  • Oruka Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ORKA→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed March 6, 2025 (10-K).

Free

Get Michael Bristow’s full pay file as a PDF — free

More than this page: up to 10 years of Michael’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Michael Bristow compensation by year

Oruka Therapeutics Summary Compensation Table · all 7 fiscal years held
In US dollars, as Oruka Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2018FY2019FY2020FY2021FY2022FY2023FY2024
Salary$304,219$284,328$286,083$343,431$345,000$345,000$96,865
Bonus$0$0$0$0$0$0$0
Stock awards$0$0$0$0$0$0$0
Option awards$0$0$619,976$162,956$0$0$39,676
Non-equity incentive$0$0$144,000$0$0$0$0
Pension and deferred compensation$0$0$0$0$0$0$0
All other$16,271$11,823$11,528$20,126$13,800$13,800$373,875
Total$320,490$296,151$1,061,587$526,513$358,800$358,800$510,416

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Oruka Therapeutics, Inc. 10-K filed March 6, 2025, accession 0001213900-25-021165, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Oruka Therapeutics, Inc. filed document, accession 0001213900-25-021165. Every figure is read from that document and cited to the page and table it appears in. Filed March 6, 2025.

$320K
$296K
$1.1M
$527K
$359K
$359K
$510K
FY18
FY19
FY20
FY21
FY22
FY23
FY24
SalaryNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
Option95,000—$4.27
Option63,333—$2.29

Per the Outstanding Equity Awards at Fiscal Year-End table in Oruka Therapeutics, Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

Oruka Therapeutics’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Thomas KeuerFormer President and Chief Operating Officer$853,520
C. Jeffrey DekkerFormer Chief Financial Officer$756,604
Lawrence KleinChief Executive Officer$520,911
Michael Bristow · this pageFormer President and Chief Executive Officer$510,416
Joana GoncalvesChief Medical Officer$317,986
Paul QuinlanGeneral Counsel$310,445

The full Oruka Therapeutics compensation record

free company brief

This page is one person within Oruka Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Oruka Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Michael Bristow's compensation dossier · One-time report. No refunds.